Authors
Latest:
Managing TLS and CRS/ICANS: Through the Lens of a First-Year Hematology/Oncology FellowTumor lysis syndrome is an oncologic emergency that every clinician will likely encounter at one time or another, and managing it requires careful consideration of a number of factors.
Latest:
Unmet Needs in the Treatment of HR+/HER2- Breast CancerClosing their discussion, the panel shares some remaining unmet needs in the treatment and management of patients with HR+/HER- breast cancer.
Latest:
Reducing Burnout Requires an Organizational ResponseA new study suggests that reducing physician burnout requires an organizational-level response that focuses on creating of a medical practice culture that value qualities such as teamwork, open communication, and process improvement.
Latest:
Dr. Silber on the Importance of Improving Clinical Trial Inclusivity in Breast CancerAndrea L. Silber, MD, discusses the importance of improving clinical trial inclusivity in breast cancer.
Latest:
Dr. Beitinjaneh on the Evaluation of Tabelecleucel in EBV+ Hematologic MalignanciesAmer M. Beitinjaneh, MD, discusses updated results from phase 3 ALLELE trial investigating the use of tabelecleucel in Epstein-Barr Virus–positive post-transplant lymphoproliferative disease following allogeneic hematopoietic stem cell transplant or solid organ transplant after failure of rituximab with or without chemotherapy.
Latest:
Dr. Chalabi on the Role of MSI Testing in CRCMyriam Chalabi, MD, discusses the utility of microsatellite instability (MSI) testing in colorectal cancer,
Latest:
How to Make Clinical Decisions With AI in OncologySpeculation on the impact of large language models or artificial intelligence in the future of health care is commonplace, causing excitement and concern.
Latest:
Dr Liao on the Value of Molecular Testing in Biliary Tract CarcinomaChih-Yi Liao, MD, discusses the value of molecular testing in biliary tract carcinoma.
Latest:
Physicians Must Become Advocates to Play a Role in Community Oncology’s FutureAlthough some community oncologists may think they can do little to abate the reimbursement reform forces that are affecting their practices, there are actions they can, and should, take to influence the success of their value-based care journey that may not be part of the fundamentals of their current practice.
Latest:
Dr. Pautier on Results of the LMS-02 Trial in Uterine and Soft Tissue SarcomasPatricia Pautier, MD, discusses the results of the phase 2 LMS-02 trial with doxorubicin and trabectedin in uterine and soft tissue leiomyosarcoma.
Latest:
Patient Selection and Sequencing of NSCLC ADCsThe panel examines which patient populations might benefit most from treatment with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and patritumab deruxtecan (HER3-DXd). Additionally, they explore potential sequencing strategies for these antibody-drug conjugates in second-line and later treatment settings.
Latest:
Looking Towards The Future of HR+/HER2- Breast CancerThe expert panel discusses ongoing research and offers closing thoughts on the future of HR+/HER2- breast cancer treatment.
Latest:
Dr Cecchini on Etrumadenant-Based Combinations in Previously Treated mCRCMichael Cecchini, MD, discusses findings from the ARC-9 trial investigating an etrumadenant-based combination in patients with previously treated mCRC.
Latest:
Dr. Zhu on Treatment Strategies for Node-Positive Prostate CancerJason Zhu, MD, discusses treatment strategies for patients with node-positive prostate cancer.
Latest:
Dr Spicer on Surgical Considerations After Approval of Perioperative Nivolumab in Resectable NSCLCJonathan D. Spicer, MD, PhD, FRCS, discusses surgical considerations for patients with for resectable NSCLC after the approval of perioperative nivolumab.
Latest:
Immunotherapy's Role in Improving Durability of Outcomes in Advanced Upper GI CancersSamuel Cytryn, MD, and David B. Zhen, MD, discuss how immunotherapy plus chemotherapy has improved the durability of outcomes in advanced GI cancers.
Latest:
Dr Alumkal on Standard Treatment Options For Patients With HRD-Altered mCRPCJoshi Alumkal, MD, discusses treatment options for patients with metastatic castrate-resistant prostate cancer harboring homologous recombination deficient alterations, including PARP inhibitors.
Latest:
Dr. Rotroff on Biomarkers Associated With the Risk of Peripheral Neuropathy in Breast CancerDaniel Rotroff, PhD, discusses the investigation of biomarkers that could help identify patients with breast cancer who are at risk for developing chemotherapy-induced peripheral neuropathy.
Latest:
LSU Health New Orleans Announces Groundbreaking Research on Remdesivir’s Novel Immunological EffectsLSU Health New Orleans is proud to announce the publication of a groundbreaking study led by Giulia Monticone PhD in the prestigious journal EMBO Reports.
Latest:
Nasr on the Need for Preclinical Models of Prostate Cancer DormancyMostafa Nasr, PhD candidate, discusses the development of novel preclinical models of prostate cancer dormancy, and the significance of these outcomes may have on future research in metastatic prostate cancer.
Latest:
Investigators Seek Simpler Solution to Treatment Resistance in Esophageal CancerAlthough the incidence, location, and histology of esophageal cancer vary globally, patients in the Western World typically develop esophageal cancer in the distal esophagus or at the gastroesophageal junction.
Latest:
Dr. Sonbol on Navigating Treatment Selection in Gastroesophageal CancersMohamad Bassam Sonbol, MD, discusses key considerations for treatment selection in patients with gastroesophageal junction cancers.
Latest:
Dr Kamdar on the Safety Profile of Liso-Cel Across Patient Subgroups in MCLManali Kamdar, MD, discusses common toxicities associated with lisocabtagene maraleucel in patients with mantle cell lymphoma.
Latest:
Dr Nayak on the Investigation of Axi-Cel in CNS LymphomaLakshmi Nayak, MD, discusses the investigation of axi-cel in patients with relapsed/refractory primary and secondary CNS lymphoma.
Latest:
Key Takeaways and Clinical Pearls in the Treatment of R/R ALLThe key opinion leaders provide concluding insights and essential recommendations regarding the management of relapsed/refractory acute lymphoblastic leukemia.
Latest:
Dr. Modi on the Utility of BTK Inhibitors in CLLDipenkumar Modi, MD, discusses the utility of BTK inhibitors in chronic lymphocytic leukemia.
Latest:
Advances Treating HR+ Metastatic Breast CancerVarious breast oncologists discuss the potential effect of treatment advances in hormone receptor-positive metastatic breast cancer.
Latest:
Dr Moreno on the Pharmacodynamics of CLN-619 in Advanced Solid TumorsVictor Moreno, MD, PhD, discusses insights into the pharmacodynamic activity of CLN-619 for patients with advanced solid tumors.
Latest:
Dr. Jagadeesh on Unmet Needs in Aggressive and Rare Lymphoma SubtypesDeepa Jagadeesh, MD, discusses unmet needs in aggressive and rare lymphoma subtypes.
Latest:
Dr. Kozuch on the Evaluation of ctDNA in the CIRCULATE-US Trial in Resected CRCPeter Kozuch, MD, discusses the phase 2/3 CIRCULATE-US trial evaluating chemotherapy decisions for patients with resected colorectal cancer based on circulating tumor DNA status.
.jpg?fit=crop&auto=format)
